• Vaccinex, Merck Collaborate on Keytruda Combo contractpharma
    September 18, 2020
    ​Vaccinex Inc., a clinical-stage biotechnology company, has entered into a clinical collaboration agreement with Merck through a subsidiary, to evaluate the combination of Vaccinex’s investigational SEMA4D inhibitor, pepinemab, and Merck’s anti-PD-1 ...
PharmaSources Customer Service